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Abstract: 2-Methoxyestradiol is one of the natural 17β-estradiol derivatives and a potential novel
anticancer agent currently being under evaluation in advanced phases of clinical trials. However,
the mechanism of anticancer action of 2-methoxyestradiol has not been yet fully established. In our
previous studies we have demonstrated that 2-methoxyestradiol selectively induces the expression
and nuclear translocation of neuronal nitric oxide synthase in osteosarcoma 143B cells. Heat shock
proteins (Hsps) are factors involved in the regulation of expression and activity of nitric oxide
synthases. Herein, we chose osteosarcoma cell lines differed in metastatic potential, metastatic 143B
and highly metastatic MG63.2 cells, in order to further investigate the anticancer mechanism of
2-methoxyestradiol. The current study aimed to determine the role of major heat shock proteins,
Hsp90 and Hsp70 in 2-methoxyestradiol-induced osteosarcoma cell death. We focused on the
implication of Hsp90 and Hsp70 in control under expression of neuronal nitric oxide synthase,
localization of the enzyme, and further generation of nitro-oxidative stress. To give the insight into
the role of Hsp90 in regulation of anticancer efficacy of 2-methoxyestradiol, we used geldanamycin
as a potent Hsp90 inhibitor. Herein, we evidenced that inhibition of Hsp90 controls the protein
expression of 2-methoxyestradiol-induced neuronal nitric oxide synthase and inhibits enzyme nuclear
translocation. We propose that decreased level of neuronal nitric oxide synthase protein after a
combined treatment with 2-methoxyestradiol and geldanamycin is directly associated with the
accompanying upregulation of Hsp70 and downregulation of Hsp90. This interaction resulted in
abrogation of anticancer efficacy of 2-methoxyestradiol by geldanamycin.
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1. Introduction
Osteosarcoma (OS) is one of the most malignant childhood bone tumors [1–3]. Clinically ineffective
treatment of osteosarcoma is often associated with the high metastatic potential of the tumor and
substantial chemoresistance [1–3]. Thus, searching for novel, potent anticancer drugs is a challenging
scientific task of highest priority.
In our previous studies using OS cell lines we established that an anticancer agent potentially
effective in therapy of osteosarcoma is 2-methoxyestradiol (2-ME) [4–9].
2-ME is one of the natural 17β-estradiol derivatives. 2-ME is also candidate for a being novel
anticancer agent [10–19]. Preclinical research suggests a wide spectrum of possible anticancer
mechanisms of 2-ME action that seem to be directly associated with the inhibition of angiogenesis
and induction of apoptosis in tumorous and proliferating cells [20–25]. Notably, normal cells are more
resistant to proapoptotic properties of 2-ME [26,27].
Consequently, 2-ME has been evaluated in different phases of clinical trials considering treatment
of various cancers [9–19], including sarcoma [16]. However, 2-ME is characterized by unfavorable
pharmacokinetic profile [10,16,19], therefore currently new formulations of 2ME are currently being
developed with the intent of increasing oral bioavailability.
Based on our previous studies we evidenced that from a mechanistic point of view, 2-ME specifically
induces the expression and nuclear translocation of neuronal nitric oxide synthase (nNOS) [4–9]. There
can be distinguished three isoforms of nitric oxide synthases (NOSs), namely nNOS (neuronal nitric
oxide synthase, Type I, NOS-1, NOS-I) found mainly in neurons, iNOS (inducible nitric oxide synthase,
Type II, NOS-2, NOS-II) induced by many stimuli like stress or inflammation in different kinds of cells
and tissues, and eNOS (endothelial nitric oxide synthase, Type III, NOS-3, NOS-III) expressed mainly
in endothelial cells [28,29]. nNOS is constitutively expressed mainly in brain tissues, but similarly was
found in a spinal cord, adrenal and ganglia glands, peripheral nitrergic nerves, kidneys, pancreatic
cells, and interestingly in vascular smooth, skeletal muscles and cardiac myocytes [28–30]. Regulation
of NOSs occurs at the levels of enzyme activity and mRNA synthesis. The nNOS mRNA is structurally
diverse as a consequence of alternative promoters and alternate splicing [31]. Notably, nNOS is a larger
protein than either eNOS and iNOS because of the N-terminal extension that contains a PDZ domain,
a consensus sequence of approximately 90 amino acids, that has been shown to mediate protein-protein
interactions (e.g., with PSD93/95, CAPON, phosphofructokinase) [28,32].
Nuclear localization of nNOS in 2-ME-treated osteosarcoma cells leads to local nitric oxide
synthesis and DNA damage, and finally, resulting in cancer and actively dividing cell death [7,8,33].
Currently, the mechanism underlying on the induction of nNOS by 2-ME has not been established.
Heat shock proteins (Hsps) are factors involved in the regulation of expression and activity of
NOSs [34–40]. Hsps regulate the activity of NOSs and therefore may limit the production of nitric
oxide and its derivatives. The Hsp70/Hsp90 chaperone machinery is responsible for the triage decision
concerning protein quality and their proteasomal ubiquitination. Notably, the oxygenase domain
of nNOS with the heme/substrate binding cleft is the site of interaction with Hsp90 protein [35].
Garcia-Cardena et al. revealed the activation of purified eNOS by Hsp90 in the absence of heme and
cofactors. They further proved that Hsp90 is an allosteric activator of eNOS [35]. Notably, Hsp90 may
also activate nNOS isoform [36]. Similarly to Hsp90, Hsp70 possesses the same binding site within
the oxygenase domain of nNOS [37]. Therefore, the overexpression of Hsp70 in contrast to Hsp90,
promotes ubiquitination and proteasomal degradation of nNOS [37,38].
There is also a paucity of data demonstrating the role of Hsp70 in the regulation of nNOS
activity [36–40]. It was further proposed that Sp and ZNF families transcription factors, together with
Oct-2, are potential candidates via which HSP70 may regulate nNOS gene expression [40].
Therefore, the aim of the study was to investigate the role of major Hsps in 2-ME anticancer mode
of action focusing on the mechanisms relying on the regulation of nNOS expression and its nuclear
translocation. We further investigated whether abrogation of Hsp90 by geldanamycin, potent Hsp90
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inhibitor [41], may interfere with anticancer efficacy of 2-ME which may be at least partially associated
with expression and localization of nNOS enzyme.
In the current study we used human metastatic OS 143B cells with established molecular response
to treatment with 2-ME [4–9]. In addition, the data were supported by results obtained on highly
metastatic mice OS MG63.2 cells [42,43]. A highly metastatic subline MG63.2 was established by
member of our team from the occasional pulmonary metastases developed from MG63 in mice [42–44].
2. Results
2.1. Anti-Proliferative Effect of 2-ME and GA
First goal of the study was to investigate whether GA impacts on anti-proliferative activity of
2-ME using metastatic 143B and highly metastatic MG63.2 cell lines.
143B and MG63.2 cells were treated with series of dilutions (0.8 µM–50 µM) of either 2-ME or GA,
or a combination of both for 24 h. Subsequently, the inhibition of 143B and MG63.2 cell growth was
observed by means of MTT-assay.
As demonstrated in Figure 1, both 2-ME and GA effectively inhibited cell growth of OS in a
concentration- and cell-dependent manner.
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Figure 1. nti-proliferative effects of 2- ethoxyestradiol (2- E) and in 143B and 63.2 cell
lines. Anti-proliferative effect of 2- E or GA, or a co bination of both co pounds in S 143B and
G63.2 cells. OS 143B (A) and 63.2 (B) were treated with series of dilutions (0.8 µ –50 µ ) of
either 2- E or GA, or a combination of both (molar ratio 1:1). The cell proliferation was consequently
determined by MTT assay. Data are presented as the mean ± SE values form at least three independent
experiments. The absence of error bar denotes a line thickness greater than the error. Data were
analyzed by GraphPad Prism Software version 6.02 performing One-way ANOVA combined with
Dunett’s Multiple Comparison Test. * p < 0.01 versus control.
Viability of 143B cells was significantly diminished from 81% to 31% (Figure 1A), whereas MG63.2
cells from 82% to 29% (Figure 1B) in the presence of series of dilutions of 2-ME (0.8 µM–50 µM) as
compared to control, respectively. Survival of 143B was reduced from 77.28% to 23.1% (Figure 1A) while
MG63.2 from 90.6% to 29.8% (Figure 1B) in the presence of series of dilutions of GA (0.8 µM–50 µM) as
compared to control.
Subsequently, 143B and MG63.2 cells were treated with combination of 2-ME and GA
(concentrations range 0.8 µM–50 µM, molar ratio 1:1). The combined treatment with 2-ME and
GA on both 143B and MG63.2 cells resulted in comparable anti-proliferative effects to compounds
when used separately (Figure 1A,B, indicated as red color). Specifically, treatment of 143B cell line
with 2-ME and GA in combination resulted in inhibition of cell proliferation from 58.3% to 21.4%
(Figure 1A). While viability of MG63.2 was diminished from 68% to 29.2% (Figure 1B).
Notably, as indicated by calculated EC50 values, MG63.2 cell line is approximately 10 times more
resistant in comparison to 143B cell line. These results confirm high metastatic potential of MG63.2 cell
line. Specifically, the EC50 values calculated for 2-ME and GA in OS 143B were equal to 0.42 µM and
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1.3 µM, respectively; while in MG63.2 were equal to 4.21 µM and 15.8 µM, respectively. While, EC50
values calculated for combination of 2-ME and GA in 143B and MG63.2 cells were at the similar level
as compared to separate treatment—1.12 µM and 15.1 µM, respectively.
2.2. A Quantitative Measure of the Degree of Drug Interaction
We have further quantitatively evaluated the degree of 2-ME and GA interaction in OS 143B
cells as representative cell line using Calcusyn software [45]. Based on the results of MTT assay, we
evaluated the median-effect plot, dose–effect curve and Fa-CI plot (Figure 2).
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Figure 2. Antagonistic effect between 2-ME and GA. Anti-proliferative potential of 2-ME (red line),
GA (green line), and the combination of both compounds (blue line) was determined by MTT assay as
described above. Consequently, median-effect plot (A), dose–effect curve (B), and Fa-CI plot (C) were
evaluated by CalcuSyn software. Values are the mean ± SE from three independent experiments.
The calculated combination index (CI) for mixture of 2-MA and GA (molar ratio 1:1) at ED50,
ED75 and ED90 was equal to 1.76165, 1.74029, 1.71927 (r = 0.98), respectively. CI more than 1 which
clearly indicates antagonism b tween compounds. The calculated Dm value for combination of 2-ME
a d GA was equal to 6.05 × 10−6 (6.05e−6) while m was value more than 1.7 indicates the hyperbolic
dose–effect curve (Figure 2).
2.3. Antagonistic Effect of 2-ME and GA in Osteosarcoma Cell Death Model
In order to further i vestigate the interaction between 2-ME and GA, we consequently investigated
the impact of the compounds on induction of OS 143B and MG 63.2 cell death using flow cytometry.
Based on the obtained anti-proliferative data and our previous studies [4–8], we chose the representative
concentrations of 2-ME equaled to 1 µM or 10 µM; while of GA equaled to 2 µM or 4 µM for the
following studies.
To etermine th influence of 24 h long treatment with either 2-ME (1 µM or 10 µM) or GA (2 µM
or 4 µM), or a combination of both on induction of cell eath in OS cells, flow cytometric-double
staining (Annexin V and PI) was performed.
As present d in Table 1, an increase in apoptotic and necrotic 143B and MG63.2 cell number
resulted from 2-ME (1 µM or 10 µM) or GA (2 µM or 4 µM), treatment was observed. Next goal f the
study w s to determine the effect of combined treatment with 2-ME and GA on cell death induction
regarding to m tastatic pot ntial of OS 143B and MG63.2 cell lines. Notably, no significant differences
between the combined and separate treatments with 2-ME and/or GA in induction of apoptosis and
necrosis were observed (Table 1).
Similarly to previous results, MG63.2 cell line was more resistant to treatment with 2-ME or GA
as compare with 143B cell line. Due to the obtained results, lack of synergistic effects f 2-ME and GA
in employed OS cell death model may be confirmed.
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Table 1. Antagonistic effects of 2-ME and GA in 143B and MG63.2 cell lines.
143B Cell Line MG63.2 Cell Line
Compound % of Apoptotic Cells % of Necrotic Cells % of Apoptotic Cells % of Necrotic Cells
Control 3% ± 1.5 5% ± 1.3% 5% ± 1.2% 4% ± 2.3%
1 µM 2-ME 13% ± 3.3%* p < 0.01
13.2% ± 5%
* p < 0.01
9.4% ± 2.4%
* p < 0.01
10.71 ± 1.3%
* p < 0.01
10 µM 2-ME 36% ± 11%**** p < 0.00001
28.5% ± 13%
**** p < 0.00001
17.2%± 2.5%
** p < 0.001
16.4% ± 4.2%
*** p < 0.0001
2 µM GA 17.5% ± 1%* p < 0.01
23.3% ± 8.3%
** p < 0.001
19.6% ± 2.8%
**** p < 0.00001
15.6% ± 3.9%
*** p < 0.0001
4 µM GA 41.5% ± 9%**** p < 0.00001
21.5% ± 3.8%
* p < 0.01
20% ± 2.5%
**** p < 0.00001
16.5% ± 5.2%
**** p < 0.00001
1 µM 2-ME
+ 2 µM GA
25.2% ± 7.4%
* p < 0.01
23.9% ± 6.8%
** p < 0.001
23.6% ± 3.7%
**** p < 0.00001
15% ± 6.6%
** p < 0.001
1 µM 2-ME
+ 4 µM GA
40% ± 14.8%
**** p < 0.00001
19.3% ± 6.2%
* p < 0.01
22.9% ± 4.3%
**** p < 0.00001
17.9% ± 1.2%
*** p < 0.0001
10 µM 2-ME
+ 2 µM GA
28% ± 14%
*** p < 0.0001
22% ± 5.3%
** p < 0.001
21.5% ± 3.5%
**** p < 0.00001
17.5% ± 1.5%
*** p < 0.0001
10 µM 2-ME
+ 4 µM GA
39.3% ± 10.2%
**** p < 0.00001
25.5% ± 3.1%
** p < 0.001
26.4% ± 1.4%
**** p < 0.00001
13.01% ± 1.7%
* p < 0.01
Induction of cell death by 2-ME, GA or combination of both compounds in OS 143B and MG63.2 cells. 143B
and MG63.2 OS cells were treated with vehiculum (Control cells), 2-ME (1 µM, 10 µM) or GA (2 µM, 4 µM) or
combination of both for 24 h. The cells were then harvested and the percentage of apoptotic and necrotic cells
was determined using Annexin V-PI staining by flow cytometry. Values are the mean ± SE of three independent
experiments (N = 6 replicate cultures). Data were analyzed by GraphPad Prism Software version 6.02 performing
one way ANOVA analyses followed by Tukey’s multiple comparison test. * p < 0.01, ** p < 0.001, *** p < 0.0001,
**** p < 0.00001 versus control.
2.4. GA Decreased 2-ME Mediated Overexpression and Nuclear Translocation of nNOS
We further verified our hypothesis whether nNOS can be directly associated with the antagonistic
effect between 2-ME and GA in OS 143B and MG63.2 cells. As we have previously reported, the highest
level of nNOS associated with nitric oxide generation observed after treatment with 2-ME was detected
between 6 h and 8 h [4–8]. Therefore herein OS 143B and MG63.2 cells were treated with either 2-ME
(1 µM or 10 µM) or GA (2 µM or 4 µM), or a combination of both for 8 h. nNOS protein level was then
determined by Western blotting and immunofluorescence (Figures 3 and 4).
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Figure 3. GA abrogates stimulatory effect of 2-ME o nNOS expressio and nuclear translocation in
143B and MG63.2 cell lines. Total pool of nNOS in OS 143B (A), MG63.2 (B) cells and in nuclear extract
of 143B cells (C) treated ith either 2-ME or GA, or a combination of both compounds. 143B and
MG63.2 OS cells were treated with vehiculum (Control), 2-ME (1 µM, 10 µM) or GA (2 µM, 4 µM) or
combination of both for 8 h. The cells were then harvested and total level of nNOS was established
by western blotting. The cytoplasmic and nuclear fractions were separated using the Nuclear Extract
Kit (Active Motif, France) according to manufacturer’s protocol. The representative data from three
experiments are presented.
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Notably, 1 µM and 10 µM 2-ME resulted in 1.5-, and 4-fold increase in the level of nNOS protein
in 143B cells, while in 2.1 and 3.3-fold change in MG63.2 cells, respectively (Figure 2). GA alone did
not significantly affect nNOS protein level. However, treatment with GA (2 µM or 4 µM) significantly
abrogated 2-ME-induced nNOS protein after 8 h of incubation in comparison to 2-ME-treated cells
(Figure 3).
Even more importantly, GA diminished the stimulatory effect of 2-ME on the nuclear translocation
of nNOS as observed in the nuclear fractions of OS 143B cells (Figure 3C). All these obtained results,
are supported by nNOS staining using immunofluorescence (Figure 4).
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2.5. Nitro-Oxidative Stress Is Involved in the Interaction between 2-ME and GA in Osteosarcoma Cells
One of anticancer approach is a stimulation of generation of ROS and RNS [46–48]. Herein, we
demonstrated that GA abrogates 2-ME-induced nuclear translocation nNOS what the most probably
results in antagonistic interaction between the compounds.
Thus, next goal of the study was to determine the total pool of nitro-oxidative stress after combined
or separated treatments of OS cells with 2-ME and GA depending on metastatic potential of OS cell
line. MG63.2 and 143B cells were treated for 8 h with either 2-ME (1 µM or 10 µM) or GA (2 µM or
4 µM), or a combination of both (Figure 5).
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As demonstrated, both 2-ME (1 µM or 10 µM) and GA (2 µM or 4 µM), when used separately
significantly increased pool of nitro-oxidative stress in 143B and MG63.2 cells after 8 h incubation
(Figure 4). The nitro-oxidative stress levels in 143B and MG63.2 after 8 h long incubation with 2-ME
or GA were comparable (Figure 5). While, incubation of 143B and MG63.2 cells with combination
of 2-ME and GA for 8 h did not result in significant changes of the level of nitro-oxidative stress
in comparison to the separate treatments (Figure 5). In addition to that, the level of ROS and RNS
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generated after combined stimulation of 143B and MG63.2 cells with 10 µM 2-ME and 2 µM or 4 µM
GA was diminished as compared to 2-ME used separately and the results were statistically significant
(Figure 5).
To further elucidate the role of nNOS in the interaction between 2-ME and GA, we used
the specific nNOS inhibitor, (N-[(4S)-4-amino-5-[(2-aminoethyl)amino]pentyl]-N-nitroguanidine
tris(trifluoroacetate)) (4-AAPNT). Previously, we demonstrated that 2 h pre-treatment with 4-AAPNT
inhibits 2-ME-induced nitro-oxidative stress [7,8]. As demonstrated, 2 h long pre-incubation of
143B and MG63.2 cells with a specific nNOS inhibitor, 10 µM 4-AAPNT, inhibited 2-ME-induced
nitro-oxidative stress confirming that 2-ME-induced stress generation is mainly due to its impact on
nNOS (Figure 5).
The nitro-oxidative stress level induced by the combined treatment with 2-ME (10 µM) and GA
(4 µM) preceded by 4-AAPNT (10 µM) pre-incubation was at similar level in comparison to OS cells
pretreated with 4-AAPNT (10 µM) and followed by treatment GA (4 µM) (Figure 5).
The obtained outcomes proposed the possible mechanism of lack of synergistic effects of 2-ME
and GA that might be at least partially associated with their influence on nNOS activity and expression
in OS cells.
2.6. Hsp90 Is Involved in the Interaction between 2-ME and GA in OS Cells
Due to the important role of Hsp90 as regulator of nNOS activity and expression [35–38], we further
investigated whether Hsp90 is involved in 2-ME-induced induction and nuclear translocation of nNOS.
Considering the consistency of the results obtained on 143B and MG63.2 cells, for further studies we
chose 143B as a representative OS cell line.
OS 143B cells were treated with 2-ME (1 µM or 10 µM) or GA (2 µM or 4 µM), or the combination
of both compounds for 8 h. Total Hsp90 (HSPC1), Hsp90 alpha (HSPC2), and Hsp90 beta (HSPC3)
gene expression and protein level were then determined by means of Real Time PCR, Western blotting
and immunofluorescence, respectively.
As demonstrated, 1 µM 2-ME had not impact on the level of Hsp90 alpha transcript (Figure 5).
In contrast, treatment with 10 µM 2-ME resulted in significant upregulation of Hsp90 alpha gene
expression by 6.7 fold (Figure 6). Treatment with both 2 µM and 4 µM GA increased Hsp90 alpha gene
expression by 9.2 and 5 fold, respectively (Figure 6). Notably, the level of Hsp90 alpha transcript after
combined treatment with 2-ME and GA was significantly downregulated in comparison to separate
treatment with the compounds (Figure 6).
Consequently, we investigated impact of 2-ME and GA on the changes of Hsp90 beta gene
expression. One micromole of 2-ME upregulated Hsp90 beta gene expression by 4.3-fold while 10 µM
2-ME did not impact on Hsp90 beta gene expression (Figure 6). Similarly to previously shown results
for Hsp90 alpha, both 2 µM and 4 µM GA significantly increased the Hsp90 beta gene expression when
used alone in comparison to the appropriate control by 3.9 and 3 fold, respectively. Notably, the level
of Hsp90 beta gene expression after 8 h of combined treatment with 2-ME and GA was significantly
diminished in comparison to cells separately treated with the compounds (Figure 6).
As demonstrated in Figure 6, the obtained results of the Hsp90 protein level are consistent with
those obtained from Real Time PCR. Both 1 µM and 10 µM 2-ME increased the total Hsp90 protein
expression by 1.8-, 1.3-fold, respectively (Figure 7A). The effect of GA on total Hsp90 protein level was
concentration-dependent (Figure 7A). Treatment of 143B cells with 2 µM GA resulted in 60% decrease,
while 4 µM GA 1.25-fold increase in the total Hsp90 protein level. Interestingly, the total level of Hsp90
protein after combined treatment of 143B with 2-ME (1 µM or 10 µM) and GA (2 µM or 4 µM) was
significantly diminished (Figure 7A,B).
We further investigated whether the influence of 2-ME and GA on the total Hsp90 protein level
was associated with their impact on Hsp90 alpha or Hsp90 beta. In consistency with Real Time PCR
results, the 8 h of treatment of 143B cells with either 10 µM 2-ME or 4 µM GA, increased the level of
Hsp90 alpha protein level by 3.2-, 5.5-fold, respectively as compared to control. While, the combined
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treatment with the compounds resulted in a significant decrease in Hsp90 alpha protein level as
compared to separate treatment with either 2-ME or GA alone (Figure 7C).
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On the contrary, 8 h of treatment with 10 µM 2-ME did not impact on the Hsp90 beta protein
level (Figure 7D). Treatment with 4 µM GA resulted in 30% increase in the Hsp90 beta protein level as
compared to control. The combined treatment with 2-ME and GA did not impact on Hsp90 beta as
compared to GA alone (Figure 7D).
2.7. Hsp70 Is Involved in the Interaction between 2-ME and GA in OS 143B Cells
Peng et al. evidenced that CHIP ligase requires Hsp70 for effective ubiquitination and proteasomal
degradation of nNOS [36,37]. Therefore, our next goal of the study was to determine the changes of
Hsp70 gene expression in OS 143B cells treated with either 2-ME (1 µM or 10 µM) or GA (2 µM or
4 µM), or a combination of both for 8 h.
As demonstrated, the separate 2-ME treatment did not influence Hsp70 gene expression in
comparison to control (Figure 8A–D). On the other hand, treatment with 2 µM or 4 µM GA resulted in a
dramatic upregulation of Hsp70 expression by 364- and 202.8-fold as compared to control, respectively
(Figure 8A–D). The combined treatment with 1 µM 2-ME and 2 µM GA; 1 µM 2-ME and 4 µM GA; 10 µM
2-ME and 2 µM GA; 10 µM 2-ME and 4 µM GA resulted in an increase of the Hsp70 gene expression
by 216-, 130-, 133-, and 138-fold as compared to control, respectively (Figure 8A–D). Nonetheless, the
overexpression of Hsp70 gene induced by the combined treatment with 2-ME and GA was significantly
diminished in comparison to the effect of GA when used separately (Figure 8A–D).
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Figure 8. 2-ME has no effect on Hsp70, while GA controls the gene a d protein expression of Hsp70 in
OS 143B cells. OS 143B cells were treated with either 2-ME (1 µM or 10 µM) or GA (2 µM or 4 µM) or in
a combination of both for 8 h. Next, Hsp70 (A–D) gene expression was determined by means of Real
Time PCR. Consequently, total pool of Hsp70 protein in OS 143B was determined by western blotting
(E) and immunofluorescence (F), respectively. Cell nuclei were shown in blue, Hsp70 immunoreactivity
in green, merged images of both in light green. Original magnification ×40. The representative data
from three experiments are presented. Data are presented as the mean ± SE values form at least three
independent experiments. The absence of error bar denotes a line thickness greater than the error.
Data were analyzed by GraphPad Prism Software version 6.02 performing one way ANOVA analyses
followed by Tukey’s multiple comparison test. ** p < 0.001, *** p < 0.0001, **** p < 0.00001 versus control.
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We further investigated the impact of the tested compounds on the Hsp70 (HSPA1) cellular protein
level by western blotting and immunofluorescence (Figure 8E,F). As demonstrated, the obtained results
of Hsp70 protein level were consistent with the results from Real Time PCR. 2-ME did not impact on
Hsp70 protein expression in comparison to control (Figure 8E,F). On the other hand, GA upregulated
Hsp70 protein level in a concentration-dependent manner as compared to control (Figure 8E,F).
Quantitative analyses revealed 5.7- and 5.1-fold upregulation of Hsp70 protein by 2 µM, and 4 µM GA,
respectively (Figure 8E).
3. Discussion
2-ME is a powerful anticancer agent that may be used in treatment of great number of malignancies,
including OS [4–19]. While there are few studies on GA-induced OS cell death [41,49–51]. Notably,
the analog of GA; 17-N-Allylamino-17-demethoxygeldanamycin, was evaluated in phase I study in
pediatric patients with recurrent or refractory solid tumors, including OS [51].
In the present study we observed the antagonistic effect between 2-ME and GA in employed OS
cell death model. A closer look into the mechanism of action of these two compounds revealed new
insight into nNOS as potential target of both 2-ME and GA. In our previous studies we showed that
2-ME drives nNOS nuclear hijacking and therefore local generation of nitric oxide leading to DNA
damage [10] and/or inhibition of mitochondrial biogenesis [4–8] in OS 143B cellular model. Herein, the
results were supported by using highly metastatic OS MG63.2 cell line [42,43].
Nuclear localization of nNOS upon activity of 2-ME is specifically interesting in light of the fact
that nNOS is believed to be essentially a cytosolic isoform [32,52,53]. While, the enzyme may be
translocated into nucleus under specific conditions [29,54,55].
Notably, in the present study we evidenced that GA, being a potent inhibitor of Hsp90, decreases
2-ME-mediated induction and nuclear translocation of nNOS independently on metastatic potential
of OS cells. Up to date, there have been no data concerning the impact of GA on the modulation of
activity or expression of nNOS. While, GA is believed to interfere with eNOS and iNOS [56,57]. species.
Mechanisms underlying on the regulation of the activity and expression of NOS are complex and
may be regulated by different factors including Hsps. It is well known that nNOS is a Hsp90-client
protein [36,58–60]. Isoforms of NOS tend to assemble hetero-complexes with Hsp90 being promptly
disassembled (dynamic cycling, “hit and run”) [61]. Hsp90 is believed to directly enhance synthesis
of nitric oxide catalyzed by nNOS, which is partially dependent on the enhancement of calmodulin
binding to nNOS [58–63]. Moreover, Hsp90 is also required for heme binding and for the formation of
catalytically active nNOS [62,63].
Two major cytoplasmic isoforms of Hsp90, inducible form Hsp90 alpha and constitutively
expressed Hsp90 beta can be distinguished [64]. As evidenced here, 2-ME in a concentration-dependent
manner upregulated both the inducible Hsp90 alpha and constitutively expressed Hsp90 beta in OS
cell death model. Currently, there are no studies concerning impact of different Hsp90 isoforms on
activity of nNOS. As suggested by Chao et al., it could be due to specific SDS-PAGE conditions [65].
Therefore, herein, for the first time, a role of Hsp90 alpha in the regulation of nNOS protein level
and nuclear localization of the enzyme was investigated. The effect of Hsp90 beta on iNOS activity
was previously reported [66]. However, this model highlighted apoptosis of human chondrocytes
and might not necessarily correspond our OS cell death model [66]. On the other hand, 2-ME was
reported to increase the level of Hsp90 alpha transcripts in breast cancer MCF-7 cell line [67]. However,
the detailed mechanism and specifically transcription factors involved in 2-ME-induced Hsp90 gene
expression have not been revealed. Previously, Hsp90 alpha has been related to the formation of the
so called “apoptotic ring” and the activation of nuclear apoptosis execution [68]. An observation of
increased protein level of Hsp90 alpha caused by 2-ME can support the hypothesis that a nuclear
localization of 2-ME-induced nNOS is associated with apoptosis of OS cells.
Herein, we presented that GA has a remarkable capability of reversing 2-ME-mediated induction
of nNOS and nuclear hijacking of the enzyme. Though, the mechanism of cytoplasm-nuclear shuttle
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of nNOS is not fully understood, we propose that Hsp90 takes part in enzyme nuclear translocation.
Indeed, nuclear translocation of the phosphoprotein Hop (Hsp70/Hsp90 organizing protein) was
established to occur under heat shock and directly associated with Hsp90 binding [69]. On the other
hand, there is evidence that nascent steroid receptors form an oligomeric complex in the cytoplasm with
Hsp90, Hsp70, and some other proteins, and dissociation of Hsp90 from the complex is prerequisite for
the nuclear transport of the receptors [70].
Indeed, GA was previously reported to impact HSP expression by stabilization of the transcription
factor HSF1 trimeric complex with HSE, and thus stimulating the induction of HSP coding genes [71].
Here, we presented that GA modulated Hsp90 gene and protein expressions in a dose-dependent
manner. As we have proved, increased Hsp90 protein expression is associated mainly with the
impact of GA on Hsp90 alpha, which correlates with its inducible potential [64]. In addition to
that, a dose-dependent effect of GA regulating Hsp90 expression has been recently demonstrated by
Karkoulis et al. [72]. The higher induction of gene expression caused by 2 µM GA as opposed to 4 µM
GA, and surprisingly enough, a decreased protein level observed after stimulation with 2 µM GA,
can be explained by compensation mechanisms and/or different mRNA stability regulation. Notably,
GA abrogated also 2-ME -induced upregulation of Hsp90 protein level which is in correlation with
decreased expression of nNOS and inhibition of its nuclear localization in employed OS cellular model.
In the case when Hsp90 does no longer chaperone the nNOS, E3 ligase interacts with Hsp70
in order to initiate protein degradation [35–37]. Hsp70 possesses the same binding site within the
oxygenase domain of nNOS as Hsp90 [36]. In light of these facts, the overexpression of Hsp70 in
contrast to Hsp90, promotes ubiquitination and proteasomal degradation of nNOS [36,37]. Thus, we
associate decreased level of nNOS protein after a combined treatment with 2-ME and GA or with GA
with the accompanying upregulation of Hsp70 and further proteasomal degradation of nNOS.
The obtained overexpression of Hsp70 after treatment with GA is also important from clinical
point of view. Importantly, 2-ME used separately did not affect Hsp70 expression. In a number
of cancers such as OS, an increased level of Hsp70, relative to the Hsp70 level in non-transformed
cells was clinically confirmed [73–76]. Inhibition of Hsp70 sensitizes cancer cells to apoptosis [36],
therefore is also linked with better outcome of chemotherapy [76]. Thus, observed in the present
study upregulation of Hsp70 by GA may be suggested as one of the main mechanisms leading to the
development of chemo-resistance [77].
All the obtained data were in consistency with pool of nitro-oxidative stress after treatment
with the compounds. Indeed, although GA cytotoxicity has been attributed to its disruption of
Hsp90 complexes, this compound also carries a benzoquinone moiety that generates reactive oxygen
species [78,79].
4. Materials and Methods
4.1. Reagents
Tissue culture media, antibiotic cocktail, heat inactivated fetal bovine serum and
2-methoxyestradiol were purchased from Sigma–Aldrich (Soborg, Denmark). The list of the primary
antibodies used in the current study is given in a Table 2 below.
In order to clarify the type of investigated Hsps, we presented the list of used antibodies, indicating
the name of protein including old and new nomenclature suggested by Kampinga et al., 2008 [80]
(Table 2).
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Table 2. The list of primary antibodies used in the current study.
Protein Clonality Clone Number Catalog Number Company
Hsp90
HSPC1 monoclonal 4F10 sc-69703
Santa Cruz Biotechology,
Inc. (Heidelberg,
Germany)
HSP90 alpha
HSPC2 polyclonal - ab2928 Abcam (Cambridge, UK)
Hsp90 beta
HSPC3 polyclonal - ab80159 Abcam (Cambridge, UK)
HSP70
HSP70-1/HSP70-2
HSPA1
HSPA1A/1B
monoclonal EP1007Y ab45133 Abcam (Cambridge, UK)
HSP60
GROEL
HSPD1
monoclonal H1 sc-13115
Santa Cruz Biotechology,
Inc. (Heidelberg,
Germany)
nNOS
NOS type I monoclonal
16/nNOS/NOS
Type I 610309
BD Biosciences (San Jose,
CA, USA)
Beta actin monoclonal C4 sc-47778
Santa Cruz Biotechology,
Inc. (Heidelberg,
Germany)
4.2. Cell Line and Culture Conditions
The human osteosarcoma 143B cell line (ATTC-8303) was purchased from Sigma–Aldrich (Soborg,
Denmark). Highly metastatic human osteosarcoma MG63.2 cell line [42–44] was established by prof.
Hue H. Luu from Department of Surgery, Orthopedic Surgery, Orthopedic Oncology and Adult
Reconstruction Associate Director, Molecular Oncology Laboratory, The University of Chicago, USA.
The cells were cultured at 37 ◦C in a humidified atmosphere saturated with 5% CO2. The cells
were maintained in monolayer culture using EMEM supplemented with 10% heat inactivated FBS,
2 mML-glutamine, penicillin (100 U/mL)/streptomycin (100 µg/mL) cocktail. For cellular treatment,
the medium supplemented only with 1% charcoal FBS was used. In order to avoid the impact of the
solvents, control cells were treated with an equal volume of the solvent used to prepare 2-ME and
GA solutions.
4.3. Cell Viability Assay (MTT Assay)
OS 143B and MG63.2 cells were treated with serial dilutions of 2-ME, GA or their combination
(molar ratio 1:1) (within the concentration range of 0.8–50 µM) of 2-ME for 24 h. The MTT assay was
performed as previously described [4–8]. The results are presented as a percentage of control. Each
experiment was performed at least three times.
4.4. Drug Dose–Effect Calculations and Analysis of Interaction Using CalcuSyn Software (Biosoft)
The CalcuSyn analysis (CalcuSyn, version 2.11, Biosoft, Cambridge, UK) was performed as
previously described [45] and as indicated in manufacturer’s protocole. The software uses the
Median-effect equation:
fa/fu = (D/Dm)m
where:
D: the dose of drug
Dm: the median-effect dose signifying the potency
fa: the fraction affected by the dose
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fu: the fraction unaffected, where fu = 1 − fa
m: an exponent signifying the sigmoidicity (shape) of the dose effect curve
The median-effect plot: A plot of x = log (D) vs y = log (fa/fu).
Dm value: the median-effect dose or concentration.
m value: a measurement of the sigmoidicity of the dose–effect curve; m = 1, >1, and <1 indicates
hyperbolic, sigmoidal, and negative sigmoidal shape, respectively.
r value: The linear correlation coefficient of the median-effect plot.
Combination index (CI): A quantitative measure of the degree of drug interaction in terms of additive
effect (CI = 1), synergism (CI < 1), or antagonism (CI > 1) for a given endpoint of the effect measurement.
4.5. Analysis of Apoptosis and Necrosis by Flow Cytometry
Rate of apoptotic and necrotic cells was analyzed by means of flow cytometry as previously
described [8]. Briefly, 143B and MG63.2 cells were seeded in 6-well plates at a density of 300,000 cells
per well. After 24 h, the cells were treated with 2-ME and GA separately or in combination for 24 h.
The cells were then trypsinased and harvested. Afterwards, the samples were incubated with Annexin
V and propidium iodide (PI) for 15 min at room temperature. The cells were then counted at 30,000,
and the fluorescence signals of Annexin V and PI conjugate were detected in the fluorescence intensity
channels FL1 and FL3 (BD FACScan, Becton-Dickinson, Franklin Lakes, NJ, USA). The obtained were
analyzed using Cyflogic software, version 1.2.1 (CyFlo Ltd., Turku, Finland). The procedure was
repeated at least 3 times to ensure repeatability of results.
4.6. Detection of Nitro-Oxidative Stress by Flow Cytometry
Reactive oxygen and nitrogen species [46] were determined using flow cytometry with
2′,7′-dichlorofluorescin diacetate (DCF-DA) staining as previously described [4–8]. Briefly, the
cells were seeded onto six-well plates at a density of 300,000 cells/ well. After 24 h of culturing in
the normal growth medium, cells were exposed to treatment with 2-ME and/or GA. DCF-DA at final
concentration of 10 µM was added to the cell medium 30 min before end of incubation. Afterward,
30,000 cells were analyzed by flow cytometry (BD FACScan, Becton-Dickinson, Franklin Lakes, NJ,
USA) and the results were analyzed by Cyflogic software, version 1.2.1 (CyFlo Ltd., Turku, Finland).
Each experiment was performed at least three times to ensure repeatability of results.
4.7. Western Blotting
Equal amounts of total cell lysates were resolved by 7% and 12% SDS-PAGE for nNOS and Hsps
analyses, respectively. The membranes were then incubated with primary antibodies anti-nNOS
(dilution 1:1000), anti-Hsp90, Hsp90 alpha, Hsp90 beta, Hsp70, Hsp60 (Table 1) (dilution 1:5000)
overnight at 4 ◦C and next, analysis performed as previously described [4–8,81]. The cytoplasmic
and nuclear fractions were separated using the Nuclear Extract Kit (Active Motif, France) according
to manufacturer’s protocol. The protein level was quantified by densitometry technique using the
Quantity one 4.5.2 software (Bio-Rad, Feldkirchen, Germany). The protein levels, as determined by
chemiluminescent quantification, were normalized relative to beta-actin levels (dilution 1:50,000). Each
experiment was performed at least three times.
4.8. RNA Extraction and Real Time PCR Analyses
The real time PCR analyses were performed as previously described [9]. Briefly, RNA was
extracted using a Total RNA Mini Plus kit (A&A Biotechnology, Gdynia, Poland) according to
the manufacturer’s protocol. The concentration and purity of isolated RNA were measured with
an Epoch spectrophotometer (BioTek, Winooski, VT, USA). Two micrograms of total RNA were
reverse transcribed into cDNA with RevertAid™ First Strand cDNA Synthesis kit according to the
Int. J. Mol. Sci. 2020, 21, 616 15 of 20
manufacturer’s instructions (Thermo Fisher Scientific Inc., USA.). The Real-Time PCR reactions were
performed in duplicates with Real-Time HS 2× PCR Master Mix SYBR® kit (A&A Biotechnology,
Gdynia, Poland). The PCR conditions were: 95 ◦C for 10 min followed by 40 cycles of denaturation for
15 s at 95 ◦C, annealing for 15 s at 60 ◦C, extension for 15 s at 72 ◦C, and fluorescence reading for 10 s at
79 ◦C. Dynamic melting curve analysis was performed for all reactions. The data were collected using
the StepOnePlus™ Real-Time PCR System (Life Technologies-Applied Biosystems, Grand Island, NY,
USA). Primers were optimized for RT-PCR target gene expression, which was normalized against the
housekeeping gene, RPL37. Statistically significant differences between treated and control cell lines
were determined using comparative delta-delta Ct test. The primer sequences used in the study are
given in Table 3 below.
Table 3. Primer sequences used in the study.
Gene Forward Primer (5′-3′) Reverse Primer (5′-3′)
HSP90AA1 (ALPHA) AGGTTGAGACGTTCGCCTTTCA AGATATCTGCACCAGCCTGCAA
HSP90AB1 (BETA) AGGAACGTACCCTGACTTTGGT ATGCCAATGCCTGTGTCTACCA
HSP70 AAGGACATCAGCCAGAACAAGCGA ACGTGTAGAAGTCGATGCCCTCAA
RPL37 TTCTGATGGCGGACTTTACC CACTTGCTCTTTCTGTGGCA
4.9. Immunofluorescence Microscopy
The immunofluorescense was performed as previously described [10]. Briefly, the cells were treated
with 2-ME and/or GA. Anti-nNOS, Hsp90, Hsp70, Hsp60 (1:50 in 0.3% GSA, 2 h incubation) (Table 1)
and secondary-conjugated with CY3 (1:100, GAM Cy3, 1 h incubation, Jackson Immunoresearch,
Suffolk, UK) antibodies were used. The images were analyzed and merged employing the ImageJ
software 1.44p. Each experiment was performed at least three times
4.10. Statistical Analysis
Data are presented as the mean ± SE values form at least three independent experiments. Data
were analyzed using GraphPad Prism (GraphPad Software, Inc., version 6.03, La Jolla, CA, USA).
Significant differences between groups were determined by One-way ANOVA combined with Tuckey’s
Multiple Comparison test.
5. Conclusions
Herein, we evidenced that inhibition of Hsp90 by GA controls the protein expression of
2-ME-induced nNOS and inhibits enzyme nuclear translocation. Based on the obtained results,
we propose that decreased level of nNOS after a combined treatment with 2-ME and GA is directly
associated with the accompanying upregulation of Hsp70 and downregulation of Hsp90. This
interaction resulted in abrogation of anticancer efficacy of 2-ME by GA.
Because of at least partly contradictory signaling pathways in OS cell death model, 2-ME and GA
should not be used in combination for cancer therapy even if the outcome of clinical trials is successful
for either one alone.
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